Ascendis Pharma Gestione
Criteri Gestione verificati 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Jan Mikkelsen
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 18.7yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 10yrs |
| Durata media del Consiglio di amministrazione | 7.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
ASND: TransCon Platform Execution And Q2 Progress Should Drive Future Upside
Analysts have modestly raised their Ascendis Pharma price target to $313 from $305, citing fresh coverage and updated models that focus on the TransCon platform's three FDA approvals, Yorvipath's commercial ramp, Yuviwel's achondroplasia launch, and renewed interest in rare endocrine disease stocks. Analyst Commentary Recent Street research on Ascendis Pharma clusters around the company’s execution on its TransCon platform and the commercial progress of Yorvipath and Yuviwel.Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Ascendis Pharma A/S ( NASDAQ:ASND ) just released its latest second-quarter results and things are looking bullish. It...
ASND: Q2 Execution And M&A Interest Will Test Fairly Priced Story
Analysts have increased their price target for Ascendis Pharma, with the updated fair value estimate moving by about $11 to $259.95. This change reflects recent target hikes around Q2 earnings previews and a growing focus on the company's execution and potential M&A interest.ASND: Rare Endocrine Execution And Q2 Earnings Should Drive Future Upside
Analysts have lifted the Ascendis Pharma fair value estimate from $293.79 to $304.60, citing updated assumptions around revenue growth, profit margins, and sector-wide price target increases that reflect greater focus on company-specific execution. Analyst Commentary Recent Street research around Ascendis Pharma points to a generally constructive outlook on the stock, with several firms adjusting price targets higher and highlighting upcoming earnings as an important test of execution.ASND: M&A Hype And Launch Expectations Will Test Lofty Share Price
Analysts have nudged their fair value estimate for Ascendis Pharma lower from $254.97 to $248.54, reflecting updated assumptions around revenue growth, profit margins, and future P/E. The revision still coincides with higher Street price targets supported by recent research highlighting potential M&A interest and product launch traction.Ascendis Pharma: Behind The Stock Surge
Summary Ascendis Pharma has more than tripled over the past two and a half years, driven by Yorvipath's blockbuster launch and Yuviwel's FDA approval. Yorvipath's rapid adoption and ongoing label expansion underpin robust revenue growth. Yuviwel-Skytrofa combo therapy demonstrated unprecedented efficacy in achondroplasia, positioning ASND ahead of competitors pending pivotal trials. Patent litigation is one risk with the stock. An analysis around Ascendis Pharma follows in the paragraphs below. Read the full article on Seeking AlphaASND: Rare Endocrine Portfolio Progress Will Drive Future Upside Potential
The analyst price target for Ascendis Pharma has moved from $342.08 to $293.79 as analysts adjust their models to reflect updated assumptions on long term growth, margins and P/E expectations, alongside recent Street research that highlights confidence in Yorvipath and ongoing target revisions. Analyst Commentary Street research on Ascendis Pharma has recently centered on Yorvipath's commercial progress, updated growth assumptions and how these feed into valuation targets and execution risk.Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position
We didn't see Ascendis Pharma A/S' ( NASDAQ:ASND ) stock surge when it reported robust earnings recently. We think that...Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?AMMINISTRATORE DELEGATO
Jan Mikkelsen (66 yo)
Mr. Jan Moller Mikkelsen is President, CEO, Member of Executive Board & Executive Director of Ascendis Pharma A/S from December 2007. He joined the Ascendis Pharma A/S in December 2007. He is Chairman of t...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 18.7yrs | Nessun dato | Nessun dato | |
| CFO, Executive VP & Member of Executive Board | 10yrs | Nessun dato | 0.0066% $ 1.1m | |
| Executive VP | 18.7yrs | Nessun dato | 0% $ 0 | |
| Executive VP | 13.2yrs | Nessun dato | 0% $ 0 | |
| Senior VP | 2.5yrs | Nessun dato | 0% $ 0 | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive Vice President of Product Supply & Quality | 11yrs | Nessun dato | 0% $ 0 | |
| Executive VP and Head of Research & Product Development | 10.6yrs | Nessun dato | 0% $ 0 | |
| Head of U.S. Commercial of Endocrinology | 4.3yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | 1.9yrs | Nessun dato | 0% $ 0 | |
| Executive VP & President of Ascendis US | 1.6yrs | Nessun dato | 0% $ 0 | |
| Chief Regulatory & Safety Officer | 1.8yrs | Nessun dato | 0% $ 0 |
Gestione esperta: Il team dirigenziale di ASND è esperto e expertise (durata media dell'incarico 10 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 18.7yrs | Nessun dato | Nessun dato | |
| Non-Executive Director | less than a year | Nessun dato | 0.0044% $ 735.2k | |
| Independent Chairman | 11.8yrs | €139.72k | 0% $ 0 | |
| Independent Director | 3.9yrs | €73.01k | 0% $ 0 | |
| Independent Director | 9.3yrs | €92.64k | 0% $ 0 | |
| Independent Director | 7.8yrs | €96.17k | 0% $ 0 | |
| Independent Director | 3.9yrs | €69.48k | 0% $ 0 |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ASND sono considerati esperti (durata media dell'incarico 7.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 00:22 |
| Prezzo dell'azione a fine giornata | 2026/08/24 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ascendis Pharma A/S è coperta da 30 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Eliana Merle | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Michelle Gilson | Canaccord Genuity |